- Home
- LPTX vs USGO Comparison
LPTX vs USGO Comparison
Compare LPTX & USGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- USGO
- Stock Information
- Founded
- LPTX 2011
- USGO 2015
- Country
- LPTX United States
- USGO Canada
- Employees
- LPTX N/A
- USGO N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- USGO Precious Metals
- Sector
- LPTX Health Care
- USGO Basic Materials
- Exchange
- LPTX Nasdaq
- USGO Nasdaq
- Market Cap
- LPTX 117.1M
- USGO 102.6M
- IPO Year
- LPTX N/A
- USGO 2023
- Fundamental
- Price
- LPTX $2.74
- USGO $8.25
- Analyst Decision
- LPTX Strong Buy
- USGO Strong Buy
- Analyst Count
- LPTX 4
- USGO 1
- Target Price
- LPTX $8.63
- USGO $24.00
- AVG Volume (30 Days)
- LPTX 452.0K
- USGO 42.3K
- Earning Date
- LPTX 11-13-2024
- USGO 11-26-2024
- Dividend Yield
- LPTX N/A
- USGO N/A
- EPS Growth
- LPTX N/A
- USGO N/A
- EPS
- LPTX N/A
- USGO N/A
- Revenue
- LPTX N/A
- USGO N/A
- Revenue This Year
- LPTX N/A
- USGO N/A
- Revenue Next Year
- LPTX N/A
- USGO N/A
- P/E Ratio
- LPTX N/A
- USGO N/A
- Revenue Growth
- LPTX N/A
- USGO N/A
- 52 Week Low
- LPTX $1.55
- USGO $5.00
- 52 Week High
- LPTX $5.00
- USGO $14.46
- Technical
- Relative Strength Index (RSI)
- LPTX 39.77
- USGO 42.22
- Support Level
- LPTX $3.40
- USGO $7.66
- Resistance Level
- LPTX $3.61
- USGO $10.49
- Average True Range (ATR)
- LPTX 0.40
- USGO 0.86
- MACD
- LPTX -0.13
- USGO -0.20
- Stochastic Oscillator
- LPTX 1.91
- USGO 20.85
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.